{"id":752011,"date":"2023-04-27T08:45:19","date_gmt":"2023-04-27T12:45:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/petvivo-holdings-inc-to-present-at-aegis-capital-virtual-conference-on-may-2-4-2023\/"},"modified":"2023-04-27T08:45:19","modified_gmt":"2023-04-27T12:45:19","slug":"petvivo-holdings-inc-to-present-at-aegis-capital-virtual-conference-on-may-2-4-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/petvivo-holdings-inc-to-present-at-aegis-capital-virtual-conference-on-may-2-4-2023\/","title":{"rendered":"PETVIVO HOLDINGS, INC. TO PRESENT AT AEGIS CAPITAL VIRTUAL CONFERENCE ON MAY 2-4, 2023"},"content":{"rendered":"
\n

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today announced it will present a company overview at the Aegis Capital Virtual Conference to be held on May 2nd \u2013 4th, 2023.<\/p>\n

John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will provide an overview of the Company\u2019s revenue-generating innovative veterinary medical device, Spryng\u2122<\/sup> with OsteoCushion\u2122<\/sup> Technology, and growth strategy. \u201cI look forward to sharing our exciting story with the Aegis conference attendees,\u201d commented Mr. Lai. \u201cWe are at an exciting moment in the evolution of our business and extremely well positioned to build on the momentum of 2022 as we continue to introduce Spryng to veterinarians throughout the United States and other parts of the world.\u201d<\/p>\n

Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and\/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.<\/p>\n

\n Conference Details:<\/strong>\n <\/p>\n

Event: Aegis Capital Virtual Conference<\/p>\n

Conference Dates: May 2nd \u2013 4th, 2023<\/p>\n

Presentation Date: Wednesday, May 3rd, 2023<\/p>\n

Presentation Time: 12:25 PM \u2013 12:55 PM ET<\/p>\n

Location: Virtual<\/p>\n

To view to presentation, visit: https:\/\/us02web.zoom.u<\/u>s<\/u>\/j\/81590540881<\/u><\/a><\/p>\n

\n About PetVivo Holdings, Inc.<\/strong>\n <\/p>\n

PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.<\/p>\n

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company\u2019s lead product SPRYNG\u2122<\/sup> with OsteoCushion\u2122<\/sup> technology, a veterinarian-administered, intraarticular injectable medical device for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.<\/p>\n

For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com<\/u><\/a> or visit https:\/\/petvivo.com\/<\/u><\/a>.<\/p>\n

CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com<\/u><\/a>
(952) 405-6216\u00a0<\/p>\n

\n Forward-Looking Statements:<\/strong>\n <\/p>\n

The foregoing material may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company\u2019s proposed development and commercial timelines, and can be identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201ccontinue\u201d or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company\u2019s business are described in detail in the Company\u2019s Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n